Bio Pharma Dive
OCTOBER 3, 2023
The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.
Pharmaceutical Technology
OCTOBER 3, 2023
Drug manufacturer Viatris has announced the divestment of a number of businesses owned by the company in a $.37bn deal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 3, 2023
The deal will hand Lilly a pipeline of experimental radioligand therapies, including a potential rival to Novartis’ Pluvicto, as well as a valuable manufacturing plant.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 3, 2023
If you believe the headlines, seaweeds can do almost anything from storing tons of carbon and stopping cows from belching methane, to making biofuels and renewable plastics – all while sustaining vibrant coastal ecosystems and feeding communities.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
OCTOBER 3, 2023
Only two of the eight biotech companies that priced offerings since July 1 trade at or above their debut share price, according to data from BioPharma Dive.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 3, 2023
Indian medical devices companies are increasingly looking to invest in innovation for developing products that help to minimize environmental footprint. Also companies like the healthtech startup HaystackAnalytics are engaged in developing India’s first Universal Infectious Disease (UID) genomic test, which highlights the need to put in place preventive health strategies.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
OCTOBER 3, 2023
NIHR awards £97.
Pharmaceutical Technology
OCTOBER 3, 2023
BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.
Pharma Times
OCTOBER 3, 2023
The Cancer Hub aims to create a world-leading ecosystem for cancer research - News - PharmaTimes
Pharmaceutical Technology
OCTOBER 3, 2023
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
Fierce Pharma
OCTOBER 3, 2023
As Galderma attempts to round out its injectable aesthetics portfolio with approvals to resolve crow’s feet and frown lines, the FDA spotted a few manufacturing wrinkles in its RelabotulinumtoxinA | The agency spotted issues relating to chemistry, manufacturing and controls (CMC) processes in the company's application for its liquid botulinum toxin type A.
Pharmaceutical Technology
OCTOBER 3, 2023
Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers.
pharmaphorum
OCTOBER 3, 2023
Digital therapeutics at a turning point: What we heard at DTx East Mike.
Pharmaceutical Technology
OCTOBER 3, 2023
Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 3, 2023
How the rise of medical device use in pharma R&D is driving wearable technology in healthcare and revolutionising the medical industry Mike.
Pharmaceutical Technology
OCTOBER 3, 2023
Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) injection
Fierce Pharma
OCTOBER 3, 2023
Four months after GSK settled a key case in California over its heartburn medication Zantac, AstraZeneca is following suit, agreeing to resolve personal injury claims over its heartburn drugs Nexiu | Four months after GSK settled a key case in California over its heartburn medication Zantac, AstraZeneca is following suit, agreeing to resolve personal injury claims over its heartburn drugs Nexium and Prilosec.
Pharmaceutical Technology
OCTOBER 3, 2023
Sanofi has signed an agreement with Janssen Pharmaceuticals for potential first-in-class vaccine against extraintestinal pathogenic E coli.
Antidote
OCTOBER 3, 2023
Clinical trials are an integral part of the medical industry, as they are required for any new treatment to be approved. Every medicine used today, whether prescription or over the counter, is a result of the rigorous research process that is a clinical trial — and for these trials to take place, volunteers are vital.
Pharmaceutical Technology
OCTOBER 3, 2023
The UK MHRA has granted authorisation for GSK's Jemperli (dostarlimab) to treat adult patients with certain endometrial cancer types.
pharmaphorum
OCTOBER 3, 2023
Finding a long-term fix to UK’s growing patient waiting list Mike.
Fierce Pharma
OCTOBER 3, 2023
After a confirmatory trial flop this past summer, Takeda is calling it quits on its targeted non-small cell lung cancer (NSCLC) drug Exkivity. | Takeda will work with the FDA to chart a voluntary withdrawal of Exkivity in the U.S., where the drug is approved for certain adult lung cancer patients whose disease has progressed on or after platinum-based chemotherapy.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
OCTOBER 3, 2023
AZ pays $425m to settle claims heartburn drugs caused harm Phil.
Fierce Pharma
OCTOBER 3, 2023
As an FDA advisory committee gears up to discuss the data supporting Amgen’s Lumakras, a pre-meeting briefing document from the agency suggests the KRAS inhibitor might have a tough road ahead. | An FDA advisory committee is set to determine if the trial was adequate and well-controlled as the agency weighs a potential full approval for Amgen's KRAS inhibitor.
pharmaphorum
OCTOBER 3, 2023
Takeda pulls Exkivity in US after failed confirmatory trial Phil.
BioSpace
OCTOBER 3, 2023
New Phase I/II trial results show that one more type 1 diabetes patient achieved insulin independence after treatment with Vertex Pharmaceuticals’ investigational stem cell therapy VX-880.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
OCTOBER 3, 2023
Exscientia trims pipeline to focus on top cancer prospects Phil.
Pharmaceutical Technology
OCTOBER 3, 2023
BGBA-3055 is under clinical development by BeiGene and currently in Phase I for Solid Tumor.
BioSpace
OCTOBER 3, 2023
In its briefing document for Thursday’s FDA advisory committee meeting, the regulator contends that the company’s confirmatory CodeBreaK 200 trial for Lumakras is not an “adequate and well-controlled” study.
Pharmaceutical Technology
OCTOBER 3, 2023
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
264 
Let's personalize your content